Suneva Medical, Inc., a privately-held aesthetics company, today announced the results of its 90-day clinical study that evaluated Regenica® Rejuvenating Dual Serum. In the study, statistically significant improvements were reported as early as 14 days, with continued improvement seen at 90 days in parameters that included the reduction in the appearance of fine lines, an increase in brightness, skin radiance and improved appearance of skin firmness and blotchiness. The study showed 95 percent overall patient satisfaction and 87 percent of patients would recommend the serum to a friend.1
Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech raised $67 million in equity financing.